Loading quotes...
Forecast
The analysts' average price target is €21.33 (+19.16%). The median is €21.38 (+19.44%).
| Buy |
7 |
| Hold |
5 |
| Sell |
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Fortrea cooperates with Omico to accelerate biomarker-driven cancer trials in Australia
Fortrea has announced a collaboration with Omico to advance precision oncology research by accelerating the identification and matching of suitable patients to biomarker-driven clinical trials. The partnership combines Fortrea’s expertise in running oncology studies with Omico’s PrOSPeCT platform, molecular profiling data and a network of investigators and trial sites in Australia. The aim is to optimize study design, enable more targeted site selection and speed patient recruitment using genomic data from more than 23,000 patients. » More on finanzen.net
Fortrea completes acquisition of Worldwide Clinical Trials' early phase services business
Fortrea has closed the purchase of Worldwide Clinical Trials' early phase services division for about $45 million. The deal includes a 200-bed CRU in San Antonio, a 60,000 sq ft GLP bioanalytical lab in Austin and a sample storage facility in Pflugerville. The acquisition brings Fortrea's global early-phase capacity to more than 570 beds and strengthens internal bioanalytical capabilities to better integrate clinical and analytical processes. It is intended to shorten turnaround times, reduce operational handoffs and expand the platform for clinical development. » More on finanzen.net
Fortrea buys early-phase unit from Worldwide for $45 million
Fortrea has signed an agreement to acquire the early‑phase division of Worldwide Clinical Trials for about $45 million in cash. The acquisition includes a 60,000‑square‑foot bioanalytical lab in Austin, a 200‑bed clinic in San Antonio and a biospecimen storage facility in Pflugerville. Fortrea thereby strengthens its Clinical Pharmacology Services and expands capacity for bioanalysis of large and small molecules, while the transaction still requires regulatory and licensing approvals. Both companies plan transition agreements to ensure continuity for customers and ongoing programs. » More on de.investing.com
Fortrea introduces Fortrea Intelligent Technology, an AI-powered suite to accelerate clinical trials
Fortrea has introduced Fortrea Intelligent Technology (FIT), a suite of people-centered, AI-powered solutions to automate workflows, optimize monitoring, and accelerate clinical trials. FIT builds on the Xcellerate platform and offers applications for biopharma, biotechnology, and medical device companies in full-service, functional-service, and SaaS models. The suite is organized into three pillars — lifecycle, foresight, and support — and provides role-based insights in near real time to improve predictability, quality, and productivity. » More on finanzen.net
Fortrea launches AI-powered technology suite Fortrea Intelligent Technology to support clinical trials
Fortrea introduced Fortrea Intelligent Technology (FIT), an AI-powered suite that includes extensions to the Xcellerate platform and new Lifecycle, Foresight and Companion modules. The tools automate workflows, integrate study data for role-specific insights and use AI/ML for pattern analysis and predictive signal generation; selected components will be offered as SaaS. The announcement comes as the stock trades below $10 and analysts project a return to profitability. » More on de.investing.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 610.49M | 2.16% |
| Gross profit | 123.16M | 40.18% |
| Net profit | 529.71K | 103.91% |
| EBITDA | 32.31M | 180.88% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.69B |
Number of shares | 94.6M |
52-week high/low | €23.80 - €7.78 |
| Dividends | No |
Beta | 1.86 |
P/E ratio | -25.99 |
PEG ratio | -0.11 |
P/B ratio | 3.52 |
P/S ratio | 0.69 |
Company profile
Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. It offers phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. is based in Durham, North Carolina.
| Name | FORTREA HOLDINGS DL-,001 Aktie |
| CEO | Anshul Thakral |
| Headquarters | Durham,
nc USA |
| Website | |
| Industry | Health Care Equipment & Supplies |
| IPO | 06/20/2023 |
| Employees | 14,000 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | FTRE |
Frankfurt | K67.F |
Düsseldorf | K67.DU |
München | K67.MU |